INC Research Announces 2017 "INCSights" Webinar Series To Advance Dialogue On Clinical Research

RALEIGH, N.C., June 06, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced its 2017 INCSights webinar series exploring the latest trends and hot topics in clinical research. The series, featuring INC experts and industry thought leaders, will provide valuable and practical knowledge on a range of topics, including rare diseases, regulatory changes, novel approaches to clinical development challenges and more.

“INC Research is excited to host this interactive webinar series that explores critical and contemporary topics that matter in the current clinical research environment,” said Judith Ng-Cashin, MD, Chief Scientific Officer. “At INC Research, our scientific mission is to improve and accelerate the availability of therapies to patients who need them.  One way we do this is by sharing the insights we’ve developed from running hundreds of clinical trials every year and working with our partners in the industry to use these insights to improve the clinical development process.”

INC’s upcoming webinar June 8, “The Good, the Bad, the Necessary in Rare Disease Studies,” will focus on the importance of establishing a robust integrated medical plan for rare disease drugs.  This will be followed by an August webinar exploring the upcoming regulatory changes for medical devices in the United States and the European Union and a September event exploring innovative approaches to oncology clinical development.

The INCSights webinar series also includes two sessions that will focus on strategies for drug developers, including the execution of large, global, Phase III programs in October. The series concludes in November with a session on how to deliver efficiencies through the functional service provider model for investigator payments.

To view the full INCSights webinar series schedule, register for the upcoming sessions, or to access the March 30 webinar, “FDA Guidance on the Assessment of Abuse Potential of Drugs – A Critical Review,” and other archived webinars hosted by INC Research, click here.

INC INCSights Series:

• June 8 – “The good, the bad, the necessary in rare disease studies”
• Aug. 24 – “Medical Devices: Reviewing regulatory changes in the U.S. and EU”
• Sept. 14 – “It’s raining innovation in Oncology clinical development – combinations, IO, umbrellas, baskets, patient centricity; key trends driving the future of cancer research”
• Oct. 3 – “What does it truly take to successfully execute large, global, Phase III programs?  INC leaders reveal a proven method to thrive in this complex environment.”
• Nov. 8  - “Delivering efficiencies via the Functional Service Provider (FSP) model for investigator payments”

About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.  Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market.  The Company was ranked “Top CRO to Work With” among the top 10 global CROs in the 2017 CenterWatch Global Investigative Site Relationship Survey.   INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.

CONTACT:

Investor Relations Contact:
Ronnie Speight
Vice President, Investor Relations
Phone: +1 (919) 745-2745
Email: Investor.Relations@incresearch.com

Press/Media Contacts:
Lori Dorer
Senior Director, Corporate Communications
Phone: +1 (919) 745-2890
Email: Corporate.Communications@incresearch.com